

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CARsgen Therapeutics Holdings Limited

科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE SOUTHBOUND STOCK CONNECT

This announcement is made voluntarily by CARsgen Therapeutics Holdings Limited (the “**Company**”, and together with its subsidiaries and consolidated affiliated entities collectively referred to as the “**Group**”).

The board of directors of the Company (the “**Board**”) is pleased to announce that, pursuant to the Notice of Adjustment of the List of Securities for Southbound Trading under the Shanghai Connect (《關於滬港通下港股通標的調整的通知》) on March 6, 2026 and the Announcement on Adjustment of the List of Eligible Securities for Southbound Trading under the Shenzhen Connect (《關於深港通下的港股通標的證券名單調整的公告》) on March 6, 2026, the shares of the Company issued and listed on The Stock Exchange of Hong Kong Limited (the “**Shares**”) have been included in the list of eligible shares for Southbound Trading of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs (collectively, the “**Stock Connect**”) with effect from March 9, 2026.

The inclusion reflects market recognition of the development potential of the Company’s core CAR-T business, operational compliance and share liquidity, and is in line with the long-term development strategy of the Company and the fundamental interests of all shareholders. Following the inclusion of the Shares into Stock Connect, eligible mainland Chinese investors may directly invest in the Shares through the Stock Connect trading systems of the Shanghai Stock Exchange and the Shenzhen Stock Exchange. This is expected to provide mainland investors with a more convenient investment channel, significantly enhance market attention and liquidity, and inject strong impetus into the Company’s capital market development.

Shareholders and potential investors should exercise caution when dealing in the shares.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, March 9, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.